Therapeutic Algorithm Guided by Sequential 11C-Choline PET/CT in a Patient With Metastatic Castration-Resistant Prostate Cancer.

Antiandrogen therapy alone or combined with radical therapy is the first choice in diagnosis and recurrence of patients with metastatic prostate cancer. However, patients on androgen deprivation frequently show treatment resistance. In recent years, new treatments for metastatic castration-resistant prostate cancer have been developed. Clinical studies with docetaxel have shown its usefulness for first-line therapy, and different therapeutic algorithms with second-line drugs like abiraterone or cabazitaxel have also been proposed. Sequential metabolic study with PET/CT imaging with ¹¹C-choline may be important for assessing the right moment for administration each one of the therapeutic options.

[1]  M. Sisani,et al.  Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view , 2014, Expert review of anticancer therapy.

[2]  F. Chierichetti,et al.  Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. , 2014, Clinical genitourinary cancer.

[3]  T. Guthrie,et al.  Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC) , 2014, BMC Urology.

[4]  Wen-Jeng Wu,et al.  Clinical predictor of survival following docetaxel-based chemotherapy , 2014, Oncology letters.

[5]  E. Ricevuto,et al.  Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer , 2014, BioMed research international.

[6]  D. Petrylak,et al.  Current management of advanced and castration resistant prostate cancer. , 2014, The Canadian journal of urology.

[7]  H. Scher,et al.  Androgen dynamics and serum PSA in patients treated with abiraterone acetate , 2014, Prostate Cancer and Prostatic Disease.

[8]  Thomas J. Smith,et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. H. van der Kwast,et al.  [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.